Mevion Medical Systems To Bring HYPERSCAN Pencil Beam Scanning Proton Therapy To The Netherlands

LITTLETON, Mass.--(BUSINESS WIRE)--The advantages of Mevion Medical Systems’ high-quality and cost-effective proton therapy technology for treating cancer are coming to the Netherlands. Zuidoost Nederland Protonen Therapie Centrum, BV (ZON-PTC) will install a MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning and Mevion’s proprietary Adaptive Aperture technology. The system delivers high-quality adaptive Intensity Modulated Proton Therapy (IMPT) treatments with precision and robustness.

“The success of Mevion’s many clinical sites clearly demonstrates that the MEVION S250 Series is the best choice for cancer centers around the world. The selection of Mevion by ZON-PTC is a further reinforcement that Mevion is the best choice”

Located on the Brightlands Maastricht Health Campus, ZON-PTC will, for the first time, make proton therapy available to patients in the southeast region of the Netherlands. Construction of the ZON-PTC facility will begin this year and the first cancer patients will be treated in 2018. The center will be affiliated with MAASTRO clinic and Maastricht University Medical Center with the aim of treating 400 cancer patients per year. Mevion was selected as the preferred vendor after a stringent tender process.

“Mevion’s compact proton therapy system will give us the ability to treat patients with the latest IMPT technology, including unparalleled treatment speed to minimize motion uncertainties and the sharpest penumbra, without the need for manual apertures and adjustments, while still being the most cost-effective proton solution,” said Geert Bosmans, project director and medical physicist of ZON-PTC. “Additionally, the system will have state-of-the-art 3D radiographic imaging to position the patient, and Mevion’s solutions offer the possibility, if needed, to expand easily in the future.”

Maria Jacobs, CEO of ZON-PTC and MAASTRO clinic said, “Thanks to Mevion’s small footprint, we can simply install the Mevion system in the space of one and a half existing conventional radiation bunkers. Mevion’s proven clinical results, small size and cost-effectiveness make it the gold standard for proton therapy systems.”

“The success of Mevion’s many clinical sites clearly demonstrates that the MEVION S250 Series is the best choice for cancer centers around the world. The selection of Mevion by ZON-PTC is a further reinforcement that Mevion is the best choice,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “At Mevion, we are proud that our low capital, operating and staffing costs, combined with our industry leading uptime, ramp-up and throughput, have contributed to ZON-PTC’s selection of the MEVION S250i Proton Therapy System.”

The MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning technology that will be installed at ZON-PTC operates at unmatched speeds. It can volumetrically scan a typical lung tumor in less than two seconds – eliminating many of the challenges that slower pencil beam scanning solutions encounter. Additionally, Mevion’s Adaptive Aperture technology includes a low-profile micro-multileaf collimator (mMLC) system designed specifically for pencil beam scanning that is capable of delivering the sharpest penumbra physically achievable with protons without the need for manual apertures and adjustments.

Proton therapy provides targeted treatment to cancer tumors and causes less damage to surrounding healthy tissue than traditional photon radiation. As the world’s smallest proton therapy system, the MEVION S250 Series is less than half the size of any other compact system and uses as little as 30% of the energy used by any other compact system, resulting in significantly lower capital, staffing and operating costs. There are currently six centers with operational Mevion proton therapy systems worldwide.

About Mevion Medical Systems®

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.

About the MEVION S250 Series™

The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefiting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The MEVION S250 Series includes:

• MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
• MEVION S250i Proton Therapy System™ with HYPERSCAN™ with Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
• MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime

The MEVION S250i Proton Therapy System with HYPERSCAN with Adaptive Aperture is not yet FDA cleared.